Acute Lymphoblastic Leukemia (ALL) – Market outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

 Acute lymphoblastic leukemia (ALL) is a malignant proliferation of lymphoid cells blocked at an early stage of differentiation that can invade the bone marrow, blood, and extramedullary sites. Although most acute lymphoblastic leukemia arises in healthy individuals, inherited genetic susceptibility and environmental risk factors have been identified in some patients. Several genetic syndromes have been identified in the pediatric population that predispose individuals to acute lymphoblastic leukemia. Common allelic variants have increased disease susceptibility with an additive effect. They are categorized into B-cell and T-cell acute lymphoblastic leukemia, characterized by chromosomal abnormalities and genetic alterations involved in the differentiation and proliferation of lymphoid precursor cells. Along with response to treatment, these abnormalities are important prognostic factors. Most ALL cases occur in children, and most deaths from ALL occur in adults. Children may do better than adults.

The incidence cases range from 1·61 to 1.92 per 100,000 Population with a male to female ratio is about and more frequently reported in children.

 

The competitive landscape of Acute Lymphoblastic Leukemia (ALL) includes country-specific approved and pipeline therapies. Any asset/product-specific designation, review, and Accelerated Approval are tracked and supplemented with analyst commentary.

KOLs insights of Acute Lymphoblastic Leukemia (ALL) across 8 MM market from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Acute Lymphoblastic Leukemia (ALL) Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Read more: Acute Lymphoblastic Leukemia (ALL) – Market outlook, Epidemiology, Market Forecast, and Competitive Landscape Report – 2021 To 2032

S. No    Asset               Company                                 Stage

1          Rylaze®            Jazz Pharmaceuticals    Phase 2

2          Marqibo® (vincristine sulfate liposomes injection)            Spectrum Pharmaceuticals, Inc     Phase 2

3          GRASPA          ERYtech Pharma          Phase 2

4          Blinatumomab   Amgen  Phase 2

5          Pyronaridine Tetraphosphate     Armaceutica, Inc.          Phase 2

6          WT1 peptide vaccine     Sellas Life Sciences Group        Phase 2

7          Ponatinib          Ariad Pharmaceuticals   Phase 2

8          Spectrila®         medac GmbH   Phase 2

9          AUTO1 Autolus Limited Phase 2

10        Liposomal Vincristine Plus Dexamethasone        Acrotech Biopharma LLC  Phase 2

Continued.